Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]:
SEC Accession No. 0001654954-17-002925
Filing Date
2017-03-31
Accepted
2017-03-31 16:16:20
Documents
80
Period of Report
2016-12-31

Document Format Files

Seq Description Document Type Size
1 FORM 10-K azrx10k_dec312016.htm 10-K 1437262
2 CERTIFICATION PURSUANT TO RULE 13A-14(A)/15D-14(A) CERTIFICATIONS SECTION 302 OF ex31-1.htm EX-31.1 16815
3 CERTIFICATE PURSUANT TO SECTION 18 U.S.C. PURSUANT TO SECTION 906 OF THE SARBANE ex32-1.htm EX-32.1 8540
  Complete submission text file 0001654954-17-002925.txt   4579752

Data Files

Seq Description Document Type Size
4 XBRL INSTANCE DOCUMENT azrx-20161231.xml EX-101.INS 787456
5 XBRL TAXONOMY EXTENSION SCHEMA azrx-20161231.xsd EX-101.SCH 51180
6 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE azrx-20161231_cal.xml EX-101.CAL 53827
7 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE azrx-20161231_def.xml EX-101.DEF 87160
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE azrx-20161231_lab.xml EX-101.LAB 259357
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE azrx-20161231_pre.xml EX-101.PRE 214286
Mailing Address 760 PARKSIDE AVENUE SUITE 304 BROOKLYN NY 11226
Business Address 760 PARKSIDE AVENUE SUITE 304 BROOKLYN NY 11226 646-699-7855
AzurRx BioPharma, Inc. (Filer) CIK: 0001604191 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE
Type: 10-K | Act: 34 | File No.: 001-37853 | Film No.: 17730567
SIC: 2834 Pharmaceutical Preparations